Showing posts from May, 2016

Earnings Analysis: Ionis Pharmaceuticals (IONS)

Stock Ratings: 1 = buy at current stock prices, 2 = buy on a 5-10% dip in stock price, 3 = sell on a 5-10% increase in stock price, 4 = sell at current stock prices to raise cash.  Ratings are based upon 12-18 month outlook on stock direction and not necessarily related to moves I make due to financial positioning.

Last week Ionis Pharmaceuticals announced their first quarter results.  The results were rather uneventful, as they posted a $-0.52 loss on earnings of $36.9M.  This was a two cent miss on earnings, but a $0.7M beat on revenues.  Everything was in line with expectations and cash was still over the $700M mark.  Progress continues on all of their phase 3 drugs and we didn't learn much more about the test that was put on clinical hold by the FDA other than the questions raised were regarding platelet counts.

As I've stated, this will continue to be a volatile and beaten down stock.  There's too much political pressure on pricing due to the current US elections,…